Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation.

ABSTRACT:

Objectives

This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use.

Background

Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks.

Methods

Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. Afte

SUBMITTER: Ng FS 

PROVIDER: S-EPMC8380655 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature